Diabetogen, Abgenix anti-CD28 antibody deal

ABGX will use its Xenomouse technology to develop a human antibody against the T cell CD28 receptor to treat Type I diabetes. ABGX and Diabetogen (London, Ontario) will both participate in preclinical...